General

“Article: PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?” has been added to your cart. View cart

Showing 1905–1920 of 2301 results

Article: PP19 NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematologic Response
€3.03 Add to cart
Article: PP2.1 Immunomodulatory effects of rapamycin in Graft versus Host Disease
€3.03 Add to cart
Article: PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS
€3.03 Add to cart
Article: PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation
€3.03 Add to cart
Article: PP2.4 Identifying infectious triggering factors even in the presence of known predisposing diseases is mandatory in hemophagocytic lymphohistiocytosis, a review of 35 cases in two Belgian hospitals
€3.03 Add to cart
Article: PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group
€3.03 Add to cart
Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium
€3.03 Add to cart
Article: PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study
€3.03 Add to cart
Article: PP22 Maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease
€3.03 Add to cart
Article: PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy
€3.03 Add to cart
Article: PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?
€3.03 Add to cart
Article: PP3.1 Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease
€3.03 Add to cart
Article: PP3.2 Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice
€3.03 Add to cart
Article: PP3.3 The ‘EBMT GVHD App’ improves accuracy of graft versus host disease assessment according to NIH criteria compared to standard practice – A proof of concept
€3.03 Add to cart
Article: PP3.4 Incidence of Cryptosporidium after autologous and allogeneic hematopoietic stem cell transplantation
€3.03 Add to cart
Article: PP3.5 The conundrum of hematocrit measurements on hematopoietic progenitor cell apheresis products: differences between cell counters
€3.03 Add to cart

Article: PP19 NEOD001 Demonstrates Organ Biomarker Responses in Patients with Light Chain Amyloidosis and Persistent Organ Dysfunction Independently of Previous Hematologic Response

Article: PP2.1 Immunomodulatory effects of rapamycin in Graft versus Host Disease

Article: PP2.2 Treatment of essential thrombocythemia in Europe: an observational study of 3649 high-risk patients in EXELS

Article: PP2.3 A novel FGA mutation underlying a case of congenital dysfibrinogenemia with unusual clinical presentation

Article: PP2.4 Identifying infectious triggering factors even in the presence of known predisposing diseases is mandatory in hemophagocytic lymphohistiocytosis, a review of 35 cases in two Belgian hospitals

Article: PP2.5 Hypercoagulability in adult sickle cell patients as compared to sickle cell trait subjects and a control group

Article: PP20 Cost-effectiveness of Ibrutinib as Frontline Treatment For Adult Patients With Chronic Lymphocytic Leukaemia in Belgium

Article: PP21 The light chain IgLV3-21 defines a new poor prognostic subgroup in Chronic Lymphocytic Leukemia: results from a multicenter study

Article: PP22 Maternal embryonic leucine zipper kinase (MELK) inhibitor OTSSP167 has preclinical activity in multiple myeloma bone disease

Article: PP23 A simple frailty score to identify patients with malignant hemopathies who don’t benefit from standard dose chemotherapy

Article: PP24 Is it possible to create an index that can predict who may never need treatment for B-CLL?

Article: PP3.1 Azacytidine prevents experimental sclerodermic chronic graft-versus-host disease

Article: PP3.2 Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice

Article: PP3.3 The ‘EBMT GVHD App’ improves accuracy of graft versus host disease assessment according to NIH criteria compared to standard practice – A proof of concept

Article: PP3.4 Incidence of Cryptosporidium after autologous and allogeneic hematopoietic stem cell transplantation

Article: PP3.5 The conundrum of hematocrit measurements on hematopoietic progenitor cell apheresis products: differences between cell counters